Research Summary

Dr. John de Groot is a neuro-oncologist specializing in the diagnosis and management of patients with primary brain and spine tumors. Dr. de Groot comes to UCSF from MD Anderson Cancer Center in Houston, Texas, where he served as director of clinical research in neuro-oncology (2013-2021) and interim chair of the Department of Neuro-Oncology (2015-2020). He joined the faculty at MD Anderson in 2004 after completing a neuro-oncology fellowship there. Dr. de Groot completed his neurology residency at Johns Hopkins University and received his medical degree from the University of Texas Medical Branch at Galveston.

Dr. de Groot is experienced in bringing new therapies from the laboratory into the clinic for treating patients with brain cancer. He has contributed to the clinical development of antiangiogenic, molecularly targeted and immunotherapy treatments for glioblastoma, and he regularly advises and collaborates with other researchers on new and developing therapies. Dr. de Groot is especially interested in the use of blood, imaging and other indirect biomarkers to evaluate the efficacy of novel therapies and is studying new approaches to overcome limitations in drug delivery to brain tumors such as through use of focused ultrasound.


  • Stanford University, BA, 1992, Human Biology
  • The University of Texas Medical Branch at Galveston, MD, 1998, Medicine
  • Johns Hopkins Bayview Medical Center, Clinical Internship, 1999, Internal Medicine
  • Johns Hopkins University School of Medicine, Clinical Residency, 2002, Neurology
  • The University of Texas MD Anderson Cancer Center, Clinical Fellowship, 2004, Neuro-Oncology

Honors & Awards

  • 1994-1995
    Dean’s List, The University of Texas Medical Branch 
  • 1995-Present
    Elected Member, Alpha Omega Alpha Honor Medical Society
  • 1996
    Student Research Fellowship, Alpha Omega Alpha Honor Medical Society 
  • 2003
    Basic Research Fellowship Award, American Brain Tumor Association 
  • 2003
    Scholarship Award, American Association for Cancer Research (AACR)
  • 2008-2010
    Career Development Award, The ASCO Cancer Foundation 

Selected Publications

  1. Sabbagh A, Beccaria K, Ling X, Marisetty A, Ott M, Caruso H, Barton E, Kong LY, Fang D, Latha K, Zhang DY, Wei J, DeGroot J, Curran MA, Rao G, Hu J, Desseaux C, Bouchoux G, Canney M, Carpentier A, Heimberger AB. Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. Clin Cancer Res. 2021 08 01; 27(15):4325-4337.  View on PubMed
  2. Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 08 17; 22(8):1073-1113.  View on PubMed
  3. Rosenthal M, Clement PM, Campone M, Gil-Gil MJ, DeGroot J, Chinot O, Idbaih A, Gan H, Raizer J, Wen PY, Pineda E, Donnet V, Mills D, El-Hashimy M, Mason W. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. ESMO Open. 2020 07; 5(4).  View on PubMed
  4. Wen PY, Rodon JA, Mason W, Beck JT, DeGroot J, Donnet V, Mills D, El-Hashimy M, Rosenthal M. Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ESMO Open. 2020 07; 5(4).  View on PubMed
  5. Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, Leu JS, Tomaszowski KH, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski RJ, Burks JK, Long JP, Kong LY, Fuller GN, DeGroot J, Sulman EP, Heimberger AB. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clin Cancer Res. 2020 09 15; 26(18):4983-4994.  View on PubMed
  6. Lee EQ, Zhang P, Wen PY, Gerstner ER, Reardon DA, Aldape KD, deGroot JF, Pan E, Raizer JJ, Kim LJ, Chmura SJ, Robins HI, Connelly JM, Battiste JD, Villano JL, Wagle N, Merrell RT, Wendland MM, Mehta MP. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.  View on PubMed
  7. Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. 2019 03 18; 35(3):504-518.e7.  View on PubMed
  8. Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer. 2018 12 01; 143(11):3019-3026.  View on PubMed
  9. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8.  View on PubMed
  10. Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol. 2014 Aug; 119(1):135-40.  View on PubMed
  11. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep 10; 31(26):3212-8.  View on PubMed
  12. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61.  View on PubMed
  13. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72.  View on PubMed

Go to UCSF Profiles, powered by CTSI